Halozyme Therapeutics, Inc. (HALO) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in San Diego, CA, United States. The current CEO is Helen I. Torley.
HALO has IPO date of 2004-03-16, 350 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $7.97B.
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company headquartered in San Diego, California, with operations across the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. The company's core proprietary technology, ENHANZE, is based on a recombinant human hyaluronidase enzyme (rHuPH20) that enables subcutaneous delivery of injectable biologics, including monoclonal antibodies and other therapeutic molecules. Halozyme develops and commercializes multiple products across oncology, immunology, and rare disease areas, including Hylenex, RITUXAN HYCELA, HYQVIA, and collaborates with leading pharmaceutical companies such as Roche, Pfizer, AbbVie, and Bristol-Myers Squibb on various therapeutic programs targeting cancer, autoimmune diseases, and infectious diseases. Founded in 1998, the company leverages its advanced drug delivery platform to enhance the efficacy and patient convenience of treatments across multiple therapeutic areas.
